BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31781384)

  • 1. Does Arterial Hypertension Affect Plasma Levels of Matrix Metalloproteinases and Their Tissue Inhibitors in Patients with Stable Coronary Artery Disease? A Preliminary Study.
    Kuliczkowski W; Banaszkiewicz M; Mysiak A; Makaś G; Bil-Lula I
    Cardiol Res Pract; 2019; 2019():6921315. PubMed ID: 31781384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of biomarker panels as predictors of severity in coronary artery disease.
    Ben Braiek A; Chahed H; Dumont F; Abdelhak F; Hichem D; Gamra H; Baudin B
    J Cell Mol Med; 2021 Feb; 25(3):1518-1530. PubMed ID: 33381894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms.
    Nanni S; Melandri G; Hanemaaijer R; Cervi V; Tomasi L; Altimari A; Van Lent N; Tricoci P; Bacchi L; Branzi A
    Transl Res; 2007 Mar; 149(3):137-44. PubMed ID: 17320799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-2, and CD40 ligand levels in patients with stable coronary artery disease.
    Tayebjee MH; Lip GY; Tan KT; Patel JV; Hughes EA; MacFadyen RJ
    Am J Cardiol; 2005 Aug; 96(3):339-45. PubMed ID: 16054454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical value of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 for the prediction and early diagnosis of coronary artery lesion in patients with Kawasaki disease].
    Peng Q; Zhou TF; Chen CH; Hua YM; Liu HM; Hong H; Zhang LY; Wu Q
    Zhonghua Er Ke Za Zhi; 2005 Sep; 43(9):676-80. PubMed ID: 16191301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating matrix metalloproteinases and their endogenous inhibitors in patients with erectile dysfunction.
    Muniz JJ; Lacchini R; Belo VA; Nobre YT; Tucci S; Martins AC; Tanus-Santos JE
    Int J Impot Res; 2012; 24(1):38-43. PubMed ID: 21918531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetes may affect the expression of matrix metalloproteinases and their inhibitors more than smoking in chronic periodontitis.
    Bastos MF; Tucci MA; de Siqueira A; de Faveri M; Figueiredo LC; Vallim PC; Duarte PM
    J Periodontal Res; 2017 Apr; 52(2):292-299. PubMed ID: 27363729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma metalloproteinase-12 and tissue inhibitor of metalloproteinase-1 levels and presence, severity, and outcome of coronary artery disease.
    Jguirim-Souissi I; Jelassi A; Addad F; Hassine M; Najah M; Ben Hamda K; Maatouk F; Ben Farhat M; Bouslema A; Rouis M; Slimane MN
    Am J Cardiol; 2007 Jul; 100(1):23-7. PubMed ID: 17599435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Metalloproteinases MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 levels in children and adolescents with type 1 diabetes].
    Florys B; Głowińska B; Urban M; Peczyńska J
    Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(3):184-9. PubMed ID: 17020653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased levels of leukocyte-derived MMP-9 in patients with stable angina pectoris.
    Jönsson S; Lundberg A; Kälvegren H; Bergström I; Szymanowski A; Jonasson L
    PLoS One; 2011 Apr; 6(4):e19340. PubMed ID: 21559401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia.
    Lorenzl S; Buerger K; Hampel H; Beal MF
    Int Psychogeriatr; 2008 Feb; 20(1):67-76. PubMed ID: 17697439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis.
    Niebroj-Dobosz I; Janik P; Sokołowska B; Kwiecinski H
    Eur J Neurol; 2010 Feb; 17(2):226-31. PubMed ID: 19796283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of MMP-9, IL-6, TNF-α levels and peripheral blood mononuclear cells genes expression of MMP-9 and TIMP-1 in Iranian patients with coronary artery disease.
    Akbari T; Kazemi Fard T; Fadaei R; Rostami R; Moradi N; Movahedi M; Fallah S
    J Cardiovasc Thorac Res; 2023; 15(4):223-230. PubMed ID: 38357561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Plasma Matrix Metalloproteinase and Tissue Inhibitors of Matrix Metalloproteinase Levels With Adverse Treatment Outcomes Among Patients With Pulmonary Tuberculosis.
    Kumar NP; Moideen K; Nancy A; Viswanathan V; Thiruvengadam K; Sivakumar S; Hissar S; Nair D; Banurekha VV; Kornfeld H; Babu S
    JAMA Netw Open; 2020 Dec; 3(12):e2027754. PubMed ID: 33258908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recanalization of arterial thrombus, and inhibition with beta-radiation in a new murine carotid occlusion model: MRNA expression of angiopoietins, metalloproteinases, and their inhibitors.
    Raymond J; Lebel V; Ogoudikpe C; Metcalfe A; Chagnon M; Robledo O
    J Vasc Surg; 2004 Dec; 40(6):1190-8. PubMed ID: 15622374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary levels of matrix metalloproteinase 9 and 2 and tissue inhibitor of matrix metalloproteinase in patients with coronary artery disease.
    Fitzsimmons PJ; Forough R; Lawrence ME; Gantt DS; Rajab MH; Kim H; Weylie B; Spiekerman AM; Dehmer GJ
    Atherosclerosis; 2007 Sep; 194(1):196-203. PubMed ID: 16942771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrix metalloproteinases and the activity of their tissue inhibitors in patients with ST-elevation myocardial infarction treated with primary angioplasty.
    Kuliczkowski W; Urbaniak J; Hallén J; Woźniak M; Poloński L; Mysiak A; Atar D; Zembala M; Serebruany V
    Kardiol Pol; 2013; 71(5):453-63. PubMed ID: 23788085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-gamma increases the ratio of matrix metalloproteinase-9/tissue inhibitor of metalloproteinase-1 in peripheral monocytes from patients with coronary artery disease.
    Springall R; Amezcua-Guerra LM; Gonzalez-Pacheco H; Furuzawa-Carballeda J; Gomez-Garcia L; Marquez-Velasco R; Mejía-Domínguez AM; Cossío-Aranda J; Martínez-Sánchez C; Bojalil R
    PLoS One; 2013; 8(8):e72291. PubMed ID: 23951304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased plasma concentration of matrix metalloproteinase-7 in patients with coronary artery disease.
    Nilsson L; Jonasson L; Nijm J; Hamsten A; Eriksson P
    Clin Chem; 2006 Aug; 52(8):1522-7. PubMed ID: 16762997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Imbalanced circulating matrix metalloproteinases in polycystic ovary syndrome.
    Gomes VA; Vieira CS; Jacob-Ferreira AL; Belo VA; Soares GM; Fernandes JB; Ferriani RA; Tanus-Santos JE
    Mol Cell Biochem; 2011 Jul; 353(1-2):251-7. PubMed ID: 21437624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.